What is the clinical evidence from this study?

Study design: Other. Population: Pancreatic ductal adenocarcinoma (PDAC) (n=362). Intervention: L3MBTL4 methylation. Primary outcome: L3MBTL4 methylation rate in PDAC.

What question did this study set out to answer?

This research explores how L3MBTL4 methylation affects therapy resistance in pancreatic ductal adenocarcinoma (PDAC).

July 26, 2026Exploration of Targeted Anti-tumor TherapyOpen Access

L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer

View Full Paper

Ask AI

Bookmark

Key result

L3MBTL4 loss sensitizes PDAC cells to DNA-PK inhibitor NU7441, with methylation affecting ~28% of tumors.

n=362

Why the study?

Does L3MBTL4 methylation sensitize pancreatic ductal adenocarcinoma cells to DNA-PK inhibitors?

Population

Pancreatic ductal adenocarcinoma cells, xenograft mouse models, and human tissue samples

Comparison

DNA-PK inhibitor and L3MBTL4 knockdown/methylation vs Control/wild-type cells and tumors

Design

Preclinical

Authors

YYY Yao YLYuan Li AGAiai Gao

Discussion

Member takes

Implication

L3MBTL4 methylation in PDAC precursors is hypothesis-generating; leaves open epigenetic targeting pending clinical validation.

Key Points

This research explores how L3MBTL4 methylation affects therapy resistance in pancreatic ductal adenocarcinoma (PDAC).
Used immunoprecipitation, siRNA knockdown, immunohistochemistry, HR and NHEJ reporter assays, comet assays, and xenograft mouse model.
Analyzed methylation prevalence in various pancreatic lesions, including PDAC.
L3MBTL4 methylation observed in 28.2% of PDAC cases.
Methylation links to tumor differentiation and size.
Loss of L3MBTL4 enhances sensitivity to DNA-PK inhibitor NU7441, both in vitro and in vivo.

Structured PICO

Does L3MBTL4 methylation sensitize pancreatic ductal adenocarcinoma cells to DNA-PK inhibitors?

Population

362 human pancreatic neoplasm samples (including 298 PDAC) and xenograft mouse models used to study L3MBTL4 methylation.

Exposure

DNA-PK inhibitor (NU7441) and L3MBTL4 knockdown/methylation

Comparator

Control/wild-type cells and tumors

Outcome

Cell proliferation, apoptosis, and sensitivity to DNA-PK inhibitor NU7441surrogate

Epigenetic silencing of L3MBTL4 sensitizes pancreatic cancer cells to DNA-PK inhibitors, suggesting a potential targeted therapeutic strategy.

Cite This Study

Yao et al. (2026) studied Pancreatic ductal adenocarcinoma (PDAC) (n=362). L3MBTL4 methylation was evaluated on L3MBTL4 methylation rate in PDAC. L3MBTL4 was methylated in 28.2% of pancreatic ductal adenocarcinomas, and its loss sensitized PDAC cells to the DNA-PK inhibitor NU7441.

synapsesocial.com/papers/6a65a660d3aea3239cd77bea https://doi.org/10.37349/etat.2026.1002382

View Full Paper

Ask AI

Bookmark

L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

L3MBTL4 methylation is a sensitive marker of DNA-PK inhibitor in pancreatic cancer

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider